0R15 7793.0 0.1028% 0R1E 7575.0 -1.8782% 0M69 None None% 0R2V 184.5 6.0345% 0QYR 1387.5 0.7991% 0QYP 405.5 -0.7344% 0LCV 141.03 0.952% 0RUK None None% 0RYA 1733.01 -1.0839% 0RIH 165.3 0.3643% 0RIH 165.3 0.3643% 0R1O 186.6 9945.7604% 0R1O None None% 0QFP None None% 0M2Z 299.0593 0.5664% 0VSO None None% 0R1I None None% 0QZI 450.5 2.7366% 0QZ0 220.0 0.0% 0NZF None None%
Last update at 2024-05-03T15:17:00Z
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -46.22100M | -49.62800M | -35.78800M | 9297.81M | -6.51800M |
| Minority interest | - | 0.00000M | 0.61M | - | - |
| Net income | -46.22300M | -56.73200M | -31.01000M | 6309.59M | -5.55900M |
| Selling general administrative | 43.06M | 12.95M | 8.37M | 11.08M | 6.54M |
| Selling and marketing expenses | 8374.56M | 7822.67M | 8662.35M | 8157.04M | - |
| Gross profit | 0.70M | 0.92M | 0.69M | 25662.37M | - |
| Reconciled depreciation | 2.49M | 0.49M | 0.28M | 1.25M | 1.12M |
| Ebit | -37.98900M | -47.72400M | -41.50700M | 11123.95M | -6.53700M |
| Ebitda | -35.49700M | -45.11100M | -39.41100M | 13326.98M | -5.37300M |
| Depreciation and amortization | 2.49M | 2.61M | 2.10M | 2203.03M | 1.16M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -42.35500M | -57.37200M | -32.61100M | 11123.95M | -6.53700M |
| Other operating expenses | 45.76M | 60.34M | 34.10M | 16883.90M | 6.54M |
| Interest expense | 0.00200M | 0.00200M | 0.00300M | 604.60M | 0.02M |
| Tax provision | 0.00200M | 0.03M | -4.77800M | -1.36000M | -0.95900M |
| Interest income | 0.51M | 9.64M | 0.24M | 0.19M | 0.03M |
| Net interest income | 0.51M | 9.64M | -2.97700M | 0.53M | 0.02M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.00200M | 7.10M | -4.77800M | 2538.42M | -0.95900M |
| Total revenue | 3.40M | 2.97M | 1.49M | 58306.23M | 0.00000M |
| Total operating expenses | 43.06M | 58.29M | 33.30M | 15759.96M | 6.54M |
| Cost of revenue | 2.70M | 2.05M | 0.80M | 32643.86M | - |
| Total other income expense net | 655.32M | -1230.36649M | -0.06200M | -1826.13573M | 0.02M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -46.22300M | -45.27600M | -35.33600M | -9.25000M | -5.55900M |
| Net income applicable to common shares | -45.60700M | -45.27600M | -34.72500M | -9.25000M | -4.93350M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 42.12M | 63.26M | 102.58M | 41.30M | 28.92M |
| Intangible assets | 14.02M | 14.02M | 18.02M | 17.12M | 18.29M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.57M | -0.00100M | -0.00100M | 4.28M | 0.11M |
| Total liab | 23.66M | 20.09M | 7.48M | 5.34M | 0.76M |
| Total stockholder equity | 18.45M | 43.17M | 95.10M | 35.96M | 28.17M |
| Deferred long term liab | - | - | - | 2.36M | 1.74M |
| Other current liab | 4.92M | 4.92M | 5.36M | 0.27M | 0.44M |
| Common stock | 0.30M | 0.24M | 0.23M | 0.19M | 0.17M |
| Capital stock | 0.30M | 0.23M | 0.23M | 0.19M | 0.17M |
| Retained earnings | -99.18400M | -52.96100M | 3.77M | 34.85M | -5.97700M |
| Other liab | - | - | 0.05M | 1.54M | - |
| Good will | 23138.45M | 23139.08M | 23139.51M | 20265.84M | - |
| Other assets | 1.10M | 1.19M | 7.17M | 2.40M | 0.96M |
| Cash | 24.68M | 41.33M | 65.16M | 13.29M | 9.29M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 16.13M | 12.21M | 7.26M | 3.38M | 0.76M |
| Current deferred revenue | -0.01000M | -18071.56332M | -14918.90193M | -13222.38744M | - |
| Net debt | -12.53200M | -28.62600M | -64.80700M | -12.67100M | -9.28800M |
| Short term debt | 4.62M | 4.82M | 0.14M | 0.21M | 0.00000M |
| Short long term debt | 4.46M | 4.66M | 0.05M | 0.12M | 0.00000M |
| Short long term debt total | 12.15M | 12.71M | 0.35M | 0.62M | - |
| Other stockholder equity | 117.34M | 95.89M | 93.01M | 2.83M | 34.56M |
| Property plant equipment | 1.19M | 2.56M | 2.49M | 0.94M | 0.28M |
| Total current assets | 28.33M | 47.43M | 76.01M | 18.90M | 9.40M |
| Long term investments | - | - | - | 1.94M | - |
| Net tangible assets | 6.97M | 30.61M | 71.46M | 18.84M | 9.88M |
| Short term investments | 1.46M | 2.74M | 9.29M | 0.98M | - |
| Net receivables | 0.91M | 2.19M | 0.02M | 0.02M | - |
| Long term debt | 7.49M | 7.68M | - | 0.13M | - |
| Inventory | 0.72M | 1.16M | 0.35M | 0.33M | - |
| Accounts payable | 11.51M | 2.46M | 1.76M | 2.90M | 0.76M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | -1.91500M | -1.91500M | -0.59500M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.19M | 0.17M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -1070.72745M | -1218.26035M | -2.94300M | 0.08M | 19.52M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 13.78M | 15.83M | 26.57M | 22.40M | 19.52M |
| Capital lease obligations | 0.20M | 0.36M | 0.30M | 0.37M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | 0.00000M | -0.66200M | 1.00M | 0.98M | 0.98M |
| Change to liabilities | 0.40M | 2.06M | 0.90M | 2.06M | 0.57M |
| Total cashflows from investing activities | - | -0.66200M | -0.75100M | -0.84900M | -9.78675M |
| Net borrowings | -3.18000M | 18.02M | -0.20200M | 0.26M | 0.26M |
| Total cash from financing activities | 15.12M | 25.52M | 77.24M | 16.54M | 26.25M |
| Change to operating activities | 5.22M | -1.94900M | 3.33M | -4.17600M | -0.08250M |
| Net income | -46.22100M | -49.62800M | -35.78800M | -10.61000M | -6.51800M |
| Change in cash | -16.65100M | -23.82600M | 51.87M | 6.00M | 9.21M |
| Begin period cash flow | 41.33M | 65.16M | 13.29M | 7.30M | 0.08M |
| End period cash flow | 24.68M | 41.33M | 65.16M | 13.29M | 9.29M |
| Total cash from operating activities | -32.67400M | -45.74500M | -24.63200M | -10.06100M | -3.99400M |
| Issuance of capital stock | 19.57M | 9.21M | 77.24M | 16.68M | 26.69M |
| Depreciation | 2.49M | 2.61M | 2.10M | -0.48500M | 1.12M |
| Other cashflows from investing activities | - | - | -0.22900M | -0.06100M | -0.06100M |
| Dividends paid | 4635.40M | 5102.44M | 5227.22M | 4721.26M | - |
| Change to inventory | 0.44M | -0.80700M | -0.02700M | -0.32600M | -0.32600M |
| Change to account receivables | -1983.08170M | -349.41953M | 1374.30M | -499.15872M | 0.16M |
| Sale purchase of stock | -1615.80469M | -3435.01024M | 5227.41M | -225.46270M | 33.54M |
| Other cashflows from financing activities | 6251.04M | 8553.95M | 5227.42M | 4946.89M | -13.04900M |
| Change to netincome | 5.26M | -0.94500M | 2.41M | 0.40M | 0.13M |
| Capital expenditures | 0.69M | 0.69M | 1.63M | 1.31M | 13.05M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 6.18M | 0.02M | 3.62M | -0.66200M | 0.87M |
| Stock based compensation | 1.56M | 7.01M | 2.18M | 1.70M | 0.53M |
| Other non cash items | 3.31M | -5.75600M | 3.27M | 0.06M | -0.95900M |
| Free cash flow | -33.36800M | -46.43900M | -26.26200M | -11.37300M | -17.04300M |
Sector: Healthcare Industry: Health Information Services
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RENX Renalytix AI plc |
-0.25 0.89% | 27.75 | - | - | 6.44 | 8.06 | 3.81 | -0.2835 |
| CRW Craneware Plc |
20.00 0.88% | 2300.00 | 85.71 | 26.53 | 3.65 | 2.44 | 3.65 | 12.32 |
| INHC Induction Healthcare Group PLC |
- -% | 12.50 | - | 21.51 | 1.76 | 0.96 | 1.48 | -1.6421 |
| COG Cambridge Cognition Holdings Plc |
- -% | 48.50 | - | 238.10 | 1.42 | 18.04 | 0.76 | -2.6598 |
| FDBK Feedback PLC |
2.50 3.03% | 85.00 | - | - | 9.56 | 0.89 | 2.29 | -0.8995 |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.
1460 Broadway, New York, NY, United States, 10036
| Name | Title | Year Born |
|---|---|---|
| Mr. James R. McCullough M.B.A. | CEO & Exec. Director | 1968 |
| Mr. Fergus Fleming | CTO & Exec. Director | 1967 |
| Mr. Thomas H. McLain CPA, M.B.A | Pres | 1959 |
| Mr. Oliver James Sterling III | Chief Financial Officer | NA |
| Ms. Andria Parks-Herrera | VP of Marketing | NA |
| Ms. Jean M. Casner | Sr. VP & Chief HR Officer | 1959 |
| Mr. Baljit Singh | Head of Clinical Operations | NA |
| Dr. Michael J. Donovan M.D., Ph.D. | Chief Medical Officer | 1954 |
| Mr. Salim Hamir F.C.A. | Company Sec. | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
UK 
AU
CA
US
NZ
Please wait processing your request...